Aeglea BioTherapeutics Inc (AGLE):企業財務及び戦略的SWOT分析

【英語タイトル】Aeglea BioTherapeutics Inc (AGLE) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH500853FSA)・商品コード:GDPH500853FSA
・発行会社(調査会社):GlobalData
・発行日:2017年1月13日
・ページ数:25
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥32,700見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥65,400見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD900 ⇒換算¥98,100見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops engineered human enzymes and companion diagnostics for the treatment of cancer. The company by combining amino acid depletion therapy with co-development of diagnostics has identified the metabolic reprogramming of cancer as an opportunity with improved therapeutic benefit. It provides treatments by utilising targeted amino acid degrading enzymes. The company’s product pipeline includes a suite of degrading enzyme treatments. Its product pipeline consists of the enzymes AEB1102, AEB3103, AEB2109, and AEB4104. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc Key Recent Developments

Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Sep 07, 2016: Aeglea BioTherapeutics Appoints Leading Experts to Inaugural Scientific Advisory Board
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer

This comprehensive SWOT profile of Aeglea BioTherapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Aeglea BioTherapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Aeglea BioTherapeutics Inc – Key Information
Aeglea BioTherapeutics Inc – Overview
Aeglea BioTherapeutics Inc – Key Employees
Aeglea BioTherapeutics Inc – Key Employee Biographies
Aeglea BioTherapeutics Inc – Key Operational Heads
Aeglea BioTherapeutics Inc – Major Products and Services
Aeglea BioTherapeutics Inc – History
Aeglea BioTherapeutics Inc – Company Statement
Aeglea BioTherapeutics Inc – Locations And Subsidiaries
Aeglea BioTherapeutics Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Aeglea BioTherapeutics Inc – Business Description
Aeglea BioTherapeutics Inc – Corporate Strategy
Aeglea BioTherapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Aeglea BioTherapeutics Inc – Strengths
Aeglea BioTherapeutics Inc – Weaknesses
Aeglea BioTherapeutics Inc – Opportunities
Aeglea BioTherapeutics Inc – Threats
Aeglea BioTherapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Aeglea BioTherapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Aeglea BioTherapeutics Inc, Key Information
Aeglea BioTherapeutics Inc, Key Ratios
Aeglea BioTherapeutics Inc, Share Data
Aeglea BioTherapeutics Inc, Major Products and Services
Aeglea BioTherapeutics Inc, History
Aeglea BioTherapeutics Inc, Key Employees
Aeglea BioTherapeutics Inc, Key Employee Biographies
Aeglea BioTherapeutics Inc, Key Operational Heads
Aeglea BioTherapeutics Inc, Other Locations
Aeglea BioTherapeutics Inc, Subsidiaries
Aeglea BioTherapeutics Inc, Key Manufacturing facilities
Aeglea BioTherapeutics Inc, Key Competitors
Aeglea BioTherapeutics Inc, SWOT Analysis
Aeglea BioTherapeutics Inc, Ratios based on current share price
Aeglea BioTherapeutics Inc, Annual Ratios
Aeglea BioTherapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Aeglea BioTherapeutics Inc, Performance Chart
Aeglea BioTherapeutics Inc, Ratio Charts

★調査レポート[Aeglea BioTherapeutics Inc (AGLE):企業財務及び戦略的SWOT分析] (コード:GDPH500853FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[Aeglea BioTherapeutics Inc (AGLE):企業財務及び戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆